Xinjiang Baihuacun Pharmaceutical Group was founded in 1959 and listed on the Shanghai Stock Exchange in 1996 (stock code: 600721), mainly engaged in pharmaceutical research and development, clinical trials, biomedicine, commercial property and other businesses
Xinjiang Baihuacun Pharmaceutical Group Co., Ltd. was founded in 1959 and is headquartered in Zhongshan Road, Urumqi City, Xinjiang. In 1996, it was listed on the Shanghai Stock Exchange with the stock code: 600721. It is mainly engaged in pharmaceutical research and development, clinical trials, biomedicine, commercial property and other businesses. The company has a sound corporate governance structure, the rules of procedure of the general meeting of shareholders, the board of directors and the board of supervisors are standardized and rigorous, and the company has 5 functional departments, 1 branch and 12 wholly-owned and holding companies.
The company has two office R&D buildings with an area of 30,000 square meters in Nanjing, Jiangsu Province, and has complete international advanced new drug research equipment and new drug R&D management system. The R&D management team with a number of doctors as the core focuses on the research of many cutting-edge technologies such as chiral synthesis, sustained and controlled release technology, targeted drug delivery system, and new molecular drug screening, and has obtained more than 100 Chinese and international PCT technology invention patents. Focusing on the technology research and development of the pharmaceutical industry, it has achieved remarkable medical technology research results, has successfully developed more than 300 new drug technologies, and obtained more than 150 new drug certificates and production approvals for domestic registration, becoming a drug research and development outsourcing service provider with a high position in the domestic industry, which can provide partners with services and integrated solutions for the whole process of new drug development from drug discovery, CMC, clinical CRO, drug registration, CMO/API supply, etc.
